ERBB2 and breast carcinoma: A phase I/II of HKI-272 in combination with trastuzumab in patients with advanced breast cancer has currently reached accrual and is awaiting data analysis.[11] It is also currently being evaluated in phase I/II studies in combination with paclitaxel as well as in combination with vinorelbine in patients with advanced breast cancer.[11] These investigations appear promising and may allow for further treatment options for patients with advanced HER2 positive breast cancers.